Rankings
▼
Calendar
ELVN
Enliven Therapeutics, Inc.
$2B
Q3 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$7M
Net Income
-$7M
EPS (Diluted)
$-1.53
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$6M
Stock-Based Comp.
$310,000
← FY 2019
All Quarters
Q4 2019 →
ELVN Q3 2019 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
